{"doi":"10.1158/2767-9764.c.6975005.v1","title":"Data from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination","abstract":"<div>Abstract<p>Immune checkpoint inhibitors improve survival in patients with mismatch repair deficiency/microsatellite instability-high (MSI-H) colorectal cancer. The recurrence outcomes following discontinuation of immunotherapy after prolonged disease control have not been definitively reported in large series. Records from patients with advanced MSI-H colorectal cancer from The University of Texas – MD Anderson Cancer Center who received immunotherapy between 2014 and 2022 and stopped after prolonged clinical benefit were reviewed. Median progression-free and overall survival were estimated. Associations between the event of recurrence and coexisting mutations <i>(KRAS/NRAS, BRAF<sup>V600E</sup></i>), metastatic organ involvement (lung, liver, lymph node, or peritoneum), metastatic timing (synchronous vs. metachronous), prior immunotherapy [anti-PD-(L)1 alone or in combination with anti-CTLA antibodies], etiology of MSI status (sporadic vs. hereditary non-polyposis colorectal cancer), and duration of immunotherapy were assessed. Sixty-four patients with MSI-H colorectal cancer without progression on immunotherapy were reviewed. Of these 48 and 16 received anti-PD(L)1 antibody alone or in combination with anti-CTLA-4 antibody, respectively. Median exposure to immunotherapy was 17.6 months (range, 1.3–51.9). After a median follow-up of 22.6 months (range, 0.3–71.7) after stopping immunotherapy, 56 of 64 patients (88%) remained without disease progression. Lung metastases were associated with recurrence/progression (OR, 6.1; <i>P</i> = 0.04), but coexisting mutation, primary tumor sidedness, and immunotherapy were not. These data provide a retrospective, single-institution analysis that showed that most patients with advanced MSI-H colorectal cancer do not recur after treatment cessation, regardless of the reason for stopping treatment or a variety of patient and disease features, supporting an optimistic prognosis of sustained disease control.</p>Significance:<p>Outcomes for patients with MSI-H colorectal cancer stopping immunotherapy after disease control remain unknown. Sixty-four patients with MSI-H colorectal cancer from our institution stopping treatment for sustained benefit or toxicity were retrospectively assessed. After median follow up of 22 months and median immunotherapy exposure of 18 months, 88% patients remained without progression. All patients who recurred or progressed and were rechallenged with immunotherapy have continued to experience disease control.</p></div>","journal":null,"year":2023,"id":414860,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":0.0,"corpus_rank":10062,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.5384,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1054018,"name":"Jane V. Thomas","orcid":"0000-0001-6682-4940","position":1,"is_corresponding":false},{"id":1054019,"name":"Kaysia Ludford","orcid":"0000-0003-3575-3611","position":2,"is_corresponding":false},{"id":678034,"name":"Jason Willis","orcid":"0000-0001-8238-8552","position":3,"is_corresponding":false},{"id":901931,"name":"Victoria Serpas Higbie","orcid":"0000-0002-4203-1142","position":4,"is_corresponding":false},{"id":264370,"name":"Kanwal Raghav","orcid":"0000-0003-1311-4173","position":5,"is_corresponding":false},{"id":461070,"name":"Benny Johnson","orcid":"0000-0003-3683-8115","position":6,"is_corresponding":false},{"id":274183,"name":"Arvind Dasari","orcid":"0000-0001-5271-9744","position":7,"is_corresponding":false},{"id":590669,"name":"Bryan K. Kee","orcid":"0000-0001-5553-2213","position":8,"is_corresponding":false},{"id":901932,"name":"Christine M. Parseghian","orcid":"0000-0002-2047-097X","position":9,"is_corresponding":false},{"id":590666,"name":"Michael S. Lee","orcid":"0000-0001-8407-3423","position":10,"is_corresponding":false},{"id":1004277,"name":"Phat H. Le","orcid":"0000-0002-9447-8149","position":11,"is_corresponding":false},{"id":423737,"name":"Maria Pia Morelli","orcid":"0009-0000-9543-6584","position":12,"is_corresponding":false},{"id":308739,"name":"John Paul Shen","orcid":"0000-0003-4588-2775","position":13,"is_corresponding":false},{"id":727321,"name":"Alisha Bent","orcid":"0000-0001-6057-213X","position":14,"is_corresponding":false},{"id":299139,"name":"Eduardo Vilar","orcid":"0000-0001-6404-3761","position":15,"is_corresponding":false},{"id":395090,"name":"Robert A. Wolff","orcid":"0000-0002-6614-1610","position":16,"is_corresponding":false},{"id":241627,"name":"Scott Kopetz","orcid":"0000-0001-9647-3416","position":17,"is_corresponding":false},{"id":274184,"name":"Michael J. Overman","orcid":"0000-0001-5377-135X","position":18,"is_corresponding":false},{"id":461072,"name":"Van K. Morris","orcid":"0000-0002-4911-2252","position":19,"is_corresponding":false},{"id":997340,"name":"Kristen Simmons","orcid":"0009-0000-3095-337X","position":0,"is_corresponding":true}],"reference_count":27,"raw_metadata":null,"created_at":"2026-07-19T01:22:08.814145Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}